Replies to post #511010 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

”And the secondary endpoints. What if after all that work and analysis and debate on ECA’s, they were not necessary after all???” — Ccie

If your last question is answered affirmatively regarding the survival endpoints, that, at minimum, would silence Ex and all bear arguments. Regardless, I believe the wait has not been solely related to ECA modification and maturity. I believe the wait, at least post five years from last patient’s enrollment, has been related to capacity to ramp this technology quickly towards SOC quantity demands.